Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
PURPOSE: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice.
METHODS: We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis.
RESULTS: By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19-specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls.
CONCLUSION: Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 15 vom: 20. Mai, Seite 2800-2814 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 19.05.2023 Date Revised 10.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT04393974 Citation Status MEDLINE |
---|
doi: |
10.1200/JCO.22.01667 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM352304553 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM352304553 | ||
003 | DE-627 | ||
005 | 20240210232500.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1200/JCO.22.01667 |2 doi | |
028 | 5 | 2 | |a pubmed24n1286.xml |
035 | |a (DE-627)NLM352304553 | ||
035 | |a (NLM)36720089 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tagliamento, Marco |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.05.2023 | ||
500 | |a Date Revised 10.02.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a ClinicalTrials.gov: NCT04393974 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice | ||
520 | |a METHODS: We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis | ||
520 | |a RESULTS: By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor-positive, 25.2% (n = 131) human epidermal growth factor receptor 2-positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19-specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls | ||
520 | |a CONCLUSION: Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Vaccines |2 NLM | |
700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
700 | 1 | |a Lambertini, Matteo |e verfasserin |4 aut | |
700 | 1 | |a Salazar, Ramon |e verfasserin |4 aut | |
700 | 1 | |a Harbeck, Nadia |e verfasserin |4 aut | |
700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
700 | 1 | |a Aguilar-Company, Juan |e verfasserin |4 aut | |
700 | 1 | |a Bower, Mark |e verfasserin |4 aut | |
700 | 1 | |a Sharkey, Rachel |e verfasserin |4 aut | |
700 | 1 | |a Dalla Pria, Alessia |e verfasserin |4 aut | |
700 | 1 | |a Plaja, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Jackson, Amanda |e verfasserin |4 aut | |
700 | 1 | |a Handford, Jasmine |e verfasserin |4 aut | |
700 | 1 | |a Sita-Lumsden, Ailsa |e verfasserin |4 aut | |
700 | 1 | |a Martinez-Vila, Clara |e verfasserin |4 aut | |
700 | 1 | |a Matas, Marta |e verfasserin |4 aut | |
700 | 1 | |a Miguel Rodriguez, Ana |e verfasserin |4 aut | |
700 | 1 | |a Vincenzi, Bruno |e verfasserin |4 aut | |
700 | 1 | |a Tonini, Giuseppe |e verfasserin |4 aut | |
700 | 1 | |a Bertuzzi, Alexia |e verfasserin |4 aut | |
700 | 1 | |a Brunet, Joan |e verfasserin |4 aut | |
700 | 1 | |a Pedrazzoli, Paolo |e verfasserin |4 aut | |
700 | 1 | |a D'Avanzo, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Biello, Federica |e verfasserin |4 aut | |
700 | 1 | |a Sinclair, Alasdair |e verfasserin |4 aut | |
700 | 1 | |a Lee, Alvin J X |e verfasserin |4 aut | |
700 | 1 | |a Rossi, Sabrina |e verfasserin |4 aut | |
700 | 1 | |a Rizzo, Gianpiero |e verfasserin |4 aut | |
700 | 1 | |a Mirallas, Oriol |e verfasserin |4 aut | |
700 | 1 | |a Pimentel, Isabel |e verfasserin |4 aut | |
700 | 1 | |a Iglesias, Maria |e verfasserin |4 aut | |
700 | 1 | |a Sanchez de Torre, Ana |e verfasserin |4 aut | |
700 | 1 | |a Guida, Annalisa |e verfasserin |4 aut | |
700 | 1 | |a Berardi, Rossana |e verfasserin |4 aut | |
700 | 1 | |a Zambelli, Alberto |e verfasserin |4 aut | |
700 | 1 | |a Tondini, Carlo |e verfasserin |4 aut | |
700 | 1 | |a Filetti, Marco |e verfasserin |4 aut | |
700 | 1 | |a Mazzoni, Francesca |e verfasserin |4 aut | |
700 | 1 | |a Mukherjee, Uma |e verfasserin |4 aut | |
700 | 1 | |a Diamantis, Nikolaos |e verfasserin |4 aut | |
700 | 1 | |a Parisi, Alessandro |e verfasserin |4 aut | |
700 | 1 | |a Aujayeb, Avinash |e verfasserin |4 aut | |
700 | 1 | |a Prat, Aleix |e verfasserin |4 aut | |
700 | 1 | |a Libertini, Michela |e verfasserin |4 aut | |
700 | 1 | |a Grisanti, Salvatore |e verfasserin |4 aut | |
700 | 1 | |a Rossi, Maura |e verfasserin |4 aut | |
700 | 1 | |a Zoratto, Federica |e verfasserin |4 aut | |
700 | 1 | |a Generali, Daniele |e verfasserin |4 aut | |
700 | 1 | |a Saura, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Lyman, Gary H |e verfasserin |4 aut | |
700 | 1 | |a Kuderer, Nicole M |e verfasserin |4 aut | |
700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 15 vom: 20. Mai, Seite 2800-2814 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2023 |g number:15 |g day:20 |g month:05 |g pages:2800-2814 |
856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.22.01667 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2023 |e 15 |b 20 |c 05 |h 2800-2814 |